Sobi Targets Thrombocytopenia In $915m Swoop For Dova

The Swedish group has got hold of the ITP and CLD drug Doptelet, widening its hematology business beyond hemophilia.

Butterflies
Sobi of Sweden hopes to fly higher buying Dova of the US • Source: Shutterstock

More from Deals

More from Business